Figure 1D shows quantitative measures of the fibroblast component α-SMA versus the epithelial component EpCAM with or without FOLFOX treatment (measured by FACS sorting). The results show that CAFs derived from SQ/FR tumor cells enrich the proportion of fibroblasts to the epithelial component (αSMA/EpCAM), compared to SQ/5-FUR, SQ/OXAR and SQ/S tumor cells. The αSMA versus EpCAM ratio is further increased with FOLFOX treated CAFS in all the tumor types (Figure 1D), confirming that CAFs are enriched in post-FOLFOX therapy on tumors. This evidence concerns the gene EPCAM and neoplasm.